Abstract
In a phase II basket trial, vemurafenib, an enzyme inhibitor prescribed for certain BRAF V600-mutant melanomas, proved effective in some nonmelanoma cancers that also carried a BRAF V600 mutation.
©2015 American Association for Cancer Research.
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Female
-
Histiocytosis / drug therapy*
-
Humans
-
Indoles / therapeutic use*
-
Male
-
Mutation*
-
Neoplasms / drug therapy*
-
Proto-Oncogene Proteins B-raf / genetics*
-
Sulfonamides / therapeutic use*
Substances
-
Antineoplastic Agents
-
Indoles
-
Sulfonamides
-
Proto-Oncogene Proteins B-raf